top of page

Headquartered in North Bethesda, Maryland, Ibex Biosciences, Inc. ("Ibex") distinguishes itself in the early-stage biotech sector with its varied research and development approach.

Ibex is committed to discovering, validating, and developing potential health solutions through investment in unconventional projects and methodologies, irrespective of their recognition within the broader research community.

 

Research & Development

Ibex boasts a diverse portfolio that includes therapeutic antibodies, gene therapies, and regenerative medicine programs.

We are proud of our proven capacity to discover and validate potential therapies from scratch, thus eliminating the need for external technology acquisitions or in-licensing.

 

Our accomplishments are underscored by a series of in-vivo studies, which have delivered remarkable efficacy against a range of challenging medical conditions.

Latest News 
patent photo.jpg

Ibex Announces New Patent Pending

Ibex announces the patent publication of Antibodies targeted to CD147

Ibex Biosciences awarded as a Top 10 Biotech Startup of 2022

Ibex recognized as an Innovative Biotech Company

bottom of page